ScholarIQanswers from OpenAlex
Bayer
FunderResearch funding and supported work
Bayer is a funder indexed in ScholarIQ from OpenAlex.
What is known about Bayer?
ScholarIQrecord summary
German multinational pharmaceutical, chemical, and agricultural biotechnology company
How many works does Bayer have?
ScholarIQindexed works
Bayer has 10,361 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Bayer?
ScholarIQopenalex
The OpenAlex for Bayer is on the source record.
What are the most-cited papers on Bayer?
ScholarIQmost cited works
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Michael Offin, Joseph M. Chan, Megan Tenet, Hira Rizvi, Ronglai Shen, Gregory J. Riely, Natasha Rekhtman, Yahya Daneshbod, Àlvaro Quintanal-Villalonga, Alexander Penson, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Dana Pe’er, Mark G. Kris, Charles M. Rudin, Helena A. Yu
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, Luis M. Ruilope, Peter Rossing, George L. Bakris, Christoph Tasto, Amer Joseph, Peter Kolkhof, Andrea Lage, Bertram Pitt, on behalf of the FIGARO-DKD Investigators
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill, Amy K. Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Meike Brinker, Robert Edfors, Na Li, Markus F. Scheerer, Charlie Scott, Masaomi Nangaku
Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors
Bertram Pitt, George L. Bakris, David A. Bushinsky, Dahlia Garza, Martha Mayo, Yuri Stasiv, Heidi Christ‐Schmidt, Lance Berman, Matthew R. Weir
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
Muthiah Vaduganathan, Gerasimos Filippatos, Brian Claggett, Akshay S. Desai, Pardeep S. Jhund, Alasdair D Henderson, Meike Brinker, Peter Kolkhof, Patrick Schloemer, James Lay‐Flurrie, Prabhakar Viswanathan, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Peter Rossing, Luís M. Ruilope, Stefan D. Anker, Bertram Pitt, Rajiv Agarwal, John J.V. McMurray, Scott D. Solomon